Particle concentration fluorescence as an alternative to radioactivity for cytokine receptor binding assays.
To detect inhibitors of the type-I interleukin-1 receptor in a safe and cost-effective nonisotopic environment, the use of particle concentration fluorescence (PCF) as a detection method for a high volume receptor binding assay (RBA) has been explored. A cell-free PCF-RBA has been developed using a soluble form of the type-I IL-1 receptor (sIL-1R), a nonneutralizing anti-sIL-1R monoclonal antibody and two fluorescein-labelled tracers: IL-1 alpha and IL-1ra fused to the Escherichia coli maltose binding protein (MBP-IL-1ra). Both ligands showed saturable specific binding (KA values in the 10(9) M-1 range), although signal intensity was about 3-fold higher with MBP-IL-1ra. The data presented here suggest that the combined use of recombinant DNA and PCF technologies can replace the traditional cell-based, radioactive RBA when screening for inhibitors of cytokine receptors.